We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+27.19%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$497M
AUM Growth
+$112M
Cap. Flow
+$51.3M
Cap. Flow %
10.33%
Top 10 Hldgs %
64.94%
Holding
41
New
10
Increased
17
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$20.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$11.4M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$10.1M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$7.94M
5
KALV
KalVista Pharmaceuticals
KALV
+$7.02M

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$28.3M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$22.5M
3
QURE icon
uniQure
QURE
+$7.01M
4
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$5.06M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
26
Viridian Therapeutics
VRDN
$2.61B
$6.07M 1.22%
+255,323
New +$6.55M
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.64B
$5.52M 1.11%
+712,798
New +$6.01M
ADAP
28
DELISTED
Adaptimmune Therapeutics
ADAP
$4.71M 0.95%
+5,095,912
New +$6.08M
OLMA icon
29
Olema Pharmaceuticals
OLMA
$899M
$4.18M 0.84%
+462,500
New +$2.79M
PHAT icon
30
Phathom Pharmaceuticals
PHAT
$743M
$4.04M 0.81%
282,332
+69,717
+33% +$804K
HARP
31
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.27M 0.46%
319,671
– –
INZY
32
DELISTED
Inozyme Pharma
INZY
$1.82M 0.37%
326,921
+93,193
+40% +$551K
VTYX
33
DELISTED
Ventyx Biosciences
VTYX
$1.04M 0.21%
+31,747
New +$1.09M
ONCR
34
DELISTED
Oncorus, Inc.
ONCR
$96.3K 0.02%
2,377,031
– –
ARQT icon
35
Arcutis Biotherapeutics
ARQT
$2.99B
– –
-254,137
Closed -$2.8M
BDTX icon
36
Black Diamond Therapeutics
BDTX
$128M
– –
-144,888
Closed -$274K
QURE icon
37
uniQure
QURE
$3.38B
– –
-348,224
Closed -$7.01M
TECX
38
Tectonic Therapeutic
TECX
$696M
– –
-53,993
Closed -$648K
TCRR
39
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-3,370,982
Closed -$5.06M
PRVB
40
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-1,173,809
Closed -$28.3M
INBX
41
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-1,192,281
Closed -$22.5M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2023 Portfolio in Review

As of Q2 2023, MPM BioImpact held 41 positions worth $497M, up 29% from $385M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

MPM BioImpact deployed $51.3M of net new capital in Q2 2023, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Intellia Therapeutics, an estimated $1.13M trimmed.

  • MPM BioImpact's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 53,399 shares worth $11.6M.
  • MPM BioImpact added most to Chinook Therapeutics, Inc. Common Stock in Q2 2023, an estimated $20.7M increase.
  • MPM BioImpact's biggest Q2 2023 reduction was Intellia Therapeutics, cutting an estimated $1.13M.
  • MPM BioImpact fully exited Provention Bio, Inc. Common Stock in Q2 2023, selling an estimated $28.3M.
  • MPM BioImpact's ten largest holdings make up 65% of its $497M portfolio in Q2 2023.
  • MPM BioImpact opened 10 new positions and closed 7 in Q2 2023.
  • MPM BioImpact's portfolio value rose 29% quarter-over-quarter to $497M.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.